IBM Watson Health, Barrow Neurological Institute identify Lou Gehrig's disease genes

IBM Watson Health and Phoenix-based Barrow Neurological Institute have identified eight genes linked with Amyotrophic Lateral Sclerosis, better known as Lou Gehrig's disease.

Barrow Neurological Institute worked with Watson for Drug Discovery, a cloud-based tool that aims to identify new drug targets through machine learning, natural language processing and other cognitive functions. Watson for Drug Discovery used published data and research about ALS to rank almost 1,500 human genes based on association with ALS.

With further study into the top 10 genes in Watson's ranking, Barrow Neurological Institute researchers determined that eight of the genes were linked with the disease. Moving forward, the researchers hope these insights will help the development of new drug targets and therapies.

More articles on health IT:
Survey: State medical boards identify telemedicine as top regulatory issue of 2016
Nuix report: 97% of security executives say human error is the No. 1 vulnerability
'Descriptive analytics are not going anywhere': 4 questions with Stamford Health's Divya Malhotra

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months